A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env
Clinical Therapeutics, July 13, 2019 https://www.clinicaltherapeutics.com/article/S0149-2918(19)30296-6/pdf